International Journal of Nanomedicine, Год журнала: 2024, Номер Volume 19, С. 13183 - 13199
Опубликована: Дек. 1, 2024
Hepatocellular carcinoma (HCC) is a deadly disease requiring the identification of new therapeutic targets and strategies.
Язык: Английский
Journal of Controlled Release, Год журнала: 2024, Номер 372, С. 446 - 466
Опубликована: Июнь 26, 2024
Язык: Английский
Процитировано
9
Biomedicine & Pharmacotherapy, Год журнала: 2023, Номер 170, С. 116059 - 116059
Опубликована: Дек. 28, 2023
The liver cancer has microenvironmental features such as low pH, M2 tumor-associated macrophage enrichment, oxygen, rich blood supply and susceptibility to hematotropic metastasis, high chemokine expression, enzyme overexpression, redox level, strong immunosuppression, which not only promotes the progression of disease, but also seriously affects clinical effectiveness traditional therapeutic approaches. However, nanotechnology, due its unique advantages size effect functionalized modifiability, can be utilized develop various responsive nano-drug delivery system (NDDS) by using these characteristic signals microenvironment a source stimulation, in turn realize intelligent release drug under specific microenvironment, significantly increase concentration at target site. Therefore, researchers have designed series stimuli-responsive NDDS based on characteristics hypoxia, weak acidity, abnormal expression proteases, they been widely investigated for improving anti-tumor efficacy reducing related side effects. This paper provides review current application progress developed response regulation treatment cancer, compares effects NDDS, reference building more advanced NDDS.
Язык: Английский
Процитировано
15
Biomaterials Science, Год журнала: 2024, Номер 12(5), С. 1131 - 1150
Опубликована: Янв. 1, 2024
Extracellular vesicles (EVs) are with lipid bilayer structures shed from the plasma membrane of cells. Microvesicles (MVs) a subset EVs containing proteins, lipids, nucleic acids, and other metabolites. MVs can be produced under specific cell stimulation conditions isolated by modern separation technology. Due to their tumor homing large volume, cell-derived microvesicles (TMVs) have attracted interest recently become excellent delivery carriers for therapeutic vaccines, imaging agents or antitumor drugs. However, preparing sufficient high-purity TMVs conducting clinical transformation has challenge in this field. In review, recent research achievements generation, isolation, characterization, modification, application cancer therapy reviewed, challenges facing applications also highlighted.
Язык: Английский
Процитировано
4
Journal of Pharmaceutical Sciences, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Journal of Functional Biomaterials, Год журнала: 2025, Номер 16(4), С. 148 - 148
Опубликована: Апрель 21, 2025
Current primary liver cancer therapies, including sorafenib and transarterial chemoembolization, face significant limitations due to chemoresistance caused by impaired drug uptake, altered metabolism, other genetic modulations. These challenges contribute relapse rates of 50–80% within five years. The need for improved treatment strategies (adjuvant therapy, unsatisfactory enhanced permeability retention (EPR) effect) has driven research into advanced delivery systems, targeted nanoparticles, biomaterials, combinatory approaches. Therefore, this review evaluates recent advancements in pharmacotherapy, focusing on the potential systems its derivatives. Approaches such as leveraging Kupffer cells tumor migration or utilizing smaller NPs inter-/intracellular delivery, address EPR limitations. Biomaterials therapies targeting have demonstrated effectiveness increasing tumor-specific but clinical evidence remains limited. Combination emerged an interesting solution overcoming broadening therapeutic functionality. Biomimetic employing blood exosomes, provide methods tumors, preventing metastasis, strengthening immune responses. However, differences between preclinical models human physiology remain a barrier translating these findings success. Future must focus development adjuvant therapy refining overcome heterogeneity low accumulation.
Язык: Английский
Процитировано
0
Chemical Engineering Journal, Год журнала: 2024, Номер 491, С. 151709 - 151709
Опубликована: Апрель 26, 2024
Язык: Английский
Процитировано
2
Colloids and Surfaces B Biointerfaces, Год журнала: 2024, Номер 241, С. 114014 - 114014
Опубликована: Июнь 5, 2024
Язык: Английский
Процитировано
1
Nanomedicine, Год журнала: 2024, Номер unknown, С. 1 - 24
Опубликована: Сен. 4, 2024
Arsenic has excellent anti-advanced liver cancer effects through a variety of pathways, but its severe systemic toxicity forces the need for safe and effective delivery strategy.
Язык: Английский
Процитировано
1
Open Medicine, Год журнала: 2024, Номер 19(1)
Опубликована: Янв. 1, 2024
Abstract Purpose This study compared the efficacy and safety of carboplatin combined with arsenic trioxide versus docetaxel in treating locally advanced cervical cancer (LACC). Methods A total 48 patients were enrolled between January 2019 December 2022 randomly assigned to experimental group (carboplatin + trioxide, n = 24) or control docetaxel, 24). The clinical efficacy, adverse reactions, serological markers analyzed. Results There was no significant difference baseline characteristics effective rates two groups (72.22% vs 68.42%, P > 0.05). Both showed reductions serum squamous cell carcinoma antigen levels after chemotherapy ( < 0.05), but observed (6.00 ± 11.36 ng/mL 8.42 12.17 ng/mL, Additionally, there incidence reactions Conclusion Arsenic as a preoperative neoadjuvant for LACC is not worse than terms short-term during treatment LACC.
Язык: Английский
Процитировано
1
Chinese Journal of Natural Medicines, Год журнала: 2024, Номер 22(12), С. 1100 - 1116
Опубликована: Дек. 1, 2024
Язык: Английский
Процитировано
1